BC Extra | Jan 7, 2020
Company News

VectivBio reunites ex-Therachon management, VCs for short bowel program

Eight months after a venture syndicate gained an exit via the sale of dwarfism company Therachon to Pfizer, the same investors have reunited to supply a $35 million round for VectivBio, a new spinout created...
BC Extra | Aug 8, 2019
Company News

BlueRock becomes Bayer's cell therapy foundation

Three years after leading the $225 million series A round for stem cell company BlueRock, Bayer is doling out $240 million in cash up front to acquire the company outright. BlueRock Therapeutics L.P. will lay...
BC Extra | Jul 29, 2019
Company News

With Mylan deal, Pfizer seeks faster growth via innovation focus

Pfizer's decision to spin out its off-patent unit and merge it with Mylan will give investors greater optionality, as management expects the remaining pharma to be a smaller but faster-growing company focused more narrowly on...
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
BC Extra | May 8, 2019
Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

Rather than file for an IPO as it had been planning to do, Therachon has elected to take a buyout offer from Pfizer, handing the pharma a clinical program to treat achondroplasia. Pfizer will pay...
BC Extra | Jan 9, 2019
Company News

Management tracks: Tak joins Flagship, Evercore taps Mehrotra

Paul-Peter Tak has stepped down from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to join Flagship Pioneering as a venture partner. He was GSK's SVP of R&D, chief immunology officer and development lead. Evercore ISI hired Ravi Mehrotra...
BC Week In Review | Aug 10, 2018
Financial News

Novo Holdings leads Therachon's $60M round

Rare disease company Therachon AG (Basel, Switzerland) said on Aug. 9 it completed a $60 million mezzanine financing led by new investor Novo Holdings. Fellow new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed...
BC Extra | Aug 9, 2018
Financial News

Novo Holdings leads Therachon's $60M round

Rare disease company Therachon AG (Basel, Switzerland) said it completed a $60 million mezzanine financing led by new investor Novo Holdings. Fellow new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed by Tekla Capital...
BC Extra | Mar 13, 2018
Company News

Management tracks: Ipsen, Illumina

Ipsen Group (Euronext:IPN; Pink:IPSEY) hired Ivana Magovcevic-Liebisch as EVP and CBO. She was EVP and chief strategy and corporate development officer at Axcella Health Inc. (Cambridge, Mass.). Genomics company Illumina Inc. (NASDAQ:ILMN) hired Phil Febbo...
BC Extra | Sep 8, 2017
Company News

Management tracks: Karolinska, Conatus, Theranexus

Life sciences investment company Karolinska Development AB (SSE:KDEV) named Fredrik Järrsten CFO effective "towards the end" of the year. He is CFO and business development director at Bactiguard Holding AB (SSE:BACTI-B). Liver disease play Conatus...
Items per page:
1 - 10 of 20
BC Extra | Jan 7, 2020
Company News

VectivBio reunites ex-Therachon management, VCs for short bowel program

Eight months after a venture syndicate gained an exit via the sale of dwarfism company Therachon to Pfizer, the same investors have reunited to supply a $35 million round for VectivBio, a new spinout created...
BC Extra | Aug 8, 2019
Company News

BlueRock becomes Bayer's cell therapy foundation

Three years after leading the $225 million series A round for stem cell company BlueRock, Bayer is doling out $240 million in cash up front to acquire the company outright. BlueRock Therapeutics L.P. will lay...
BC Extra | Jul 29, 2019
Company News

With Mylan deal, Pfizer seeks faster growth via innovation focus

Pfizer's decision to spin out its off-patent unit and merge it with Mylan will give investors greater optionality, as management expects the remaining pharma to be a smaller but faster-growing company focused more narrowly on...
BioCentury | Jun 29, 2019
Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
BC Extra | May 8, 2019
Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

Rather than file for an IPO as it had been planning to do, Therachon has elected to take a buyout offer from Pfizer, handing the pharma a clinical program to treat achondroplasia. Pfizer will pay...
BC Extra | Jan 9, 2019
Company News

Management tracks: Tak joins Flagship, Evercore taps Mehrotra

Paul-Peter Tak has stepped down from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to join Flagship Pioneering as a venture partner. He was GSK's SVP of R&D, chief immunology officer and development lead. Evercore ISI hired Ravi Mehrotra...
BC Week In Review | Aug 10, 2018
Financial News

Novo Holdings leads Therachon's $60M round

Rare disease company Therachon AG (Basel, Switzerland) said on Aug. 9 it completed a $60 million mezzanine financing led by new investor Novo Holdings. Fellow new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed...
BC Extra | Aug 9, 2018
Financial News

Novo Holdings leads Therachon's $60M round

Rare disease company Therachon AG (Basel, Switzerland) said it completed a $60 million mezzanine financing led by new investor Novo Holdings. Fellow new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed by Tekla Capital...
BC Extra | Mar 13, 2018
Company News

Management tracks: Ipsen, Illumina

Ipsen Group (Euronext:IPN; Pink:IPSEY) hired Ivana Magovcevic-Liebisch as EVP and CBO. She was EVP and chief strategy and corporate development officer at Axcella Health Inc. (Cambridge, Mass.). Genomics company Illumina Inc. (NASDAQ:ILMN) hired Phil Febbo...
BC Extra | Sep 8, 2017
Company News

Management tracks: Karolinska, Conatus, Theranexus

Life sciences investment company Karolinska Development AB (SSE:KDEV) named Fredrik Järrsten CFO effective "towards the end" of the year. He is CFO and business development director at Bactiguard Holding AB (SSE:BACTI-B). Liver disease play Conatus...
Items per page:
1 - 10 of 20